<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054179</url>
  </required_header>
  <id_info>
    <org_study_id>PIFB Catheter RCT</org_study_id>
    <nct_id>NCT05054179</nct_id>
  </id_info>
  <brief_title>Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain</brief_title>
  <official_title>The Efficacy of Pecto-intercostal Fascial Plane Catheters for Reduction of Sternal Pain in Cardiac Surgery Patients With Complete Median Sternotomy: A Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the most painful aspects of open heart surgery is the incision made through the skin&#xD;
      and the sternum to access the heart (a &quot;sternotomy&quot;). Post-sternotomy pain is a potentially&#xD;
      debilitating complication of surgery that slows recovery immediately after surgery and can&#xD;
      lead to issues with chronic pain. Previous research has shown that by injecting local&#xD;
      anesthesia in the pecto-intercostal fascial plane, the space between the pectoralis major and&#xD;
      the intercostal muscles, pain relief can be provided. This study aims to evaluate whether&#xD;
      continuous local anesthetic infusion through multi-orifice pecto-intercostal fascial plane&#xD;
      block (PIFB) catheters can reduce acute sternal pain after cardiac surgery via a complete&#xD;
      median sternotomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Justification:&#xD;
&#xD;
      Post-sternotomy pain after cardiac surgery can be debilitating and associated with increased&#xD;
      risk of complications, including poor respiratory mechanics and persistent post-sternotomy&#xD;
      pain. Sternal pain after cardiac surgery typically result in an average score of 3-7 on an&#xD;
      11-point numeric rating scale. The sternum is innervated by the medial division of the&#xD;
      anterior cutaneous branches of the T2-6 intercostal nerves.&#xD;
&#xD;
      Concern for epidural hematoma in the context of systemic heparinization with cardiac surgery&#xD;
      deters most institutions from utilizing neuraxial analgesia for post-sternotomy pain.&#xD;
      Parasternal regional blockades such as pecto-intercostal fascial plane block (PIFB) can&#xD;
      provide a low-risk alternative. PIFB consists of parasternal injection deep to the pectoralis&#xD;
      major muscle and superficial to the internal intercostal muscle. A superficial blockade such&#xD;
      as PIFB may be safer and technically easier to perform than a deeper block such as the&#xD;
      transversus thoracic plane block (TTPB), with theoretical risks of pleural puncture, internal&#xD;
      thoracic artery (ITA) injury, and limited spread secondary to tissue plane disruption after&#xD;
      ITA harvest.However, after a single-injection PIFB, spread may not be adequate. Adequate&#xD;
      spread can be achieved with multiple injections or multi-orifice catheters. As&#xD;
      post-sternotomy pain remains severe for two postoperative days, multi-orifice catheters may&#xD;
      be more beneficial than single-shot injections with limited duration of action.&#xD;
&#xD;
      Purpose:&#xD;
&#xD;
      The purpose of this study is to evaluate whether continuous local anesthetic infusion through&#xD;
      multi-orifice PIFB catheters can reduce acute sternal pain after cardiac surgery via a&#xD;
      complete median sternotomy. The 24 hour time point was chosen because it represents a time&#xD;
      where both the post-sternotomy pain is rated as severe, especially with movement and&#xD;
      coughing, and the patient is required to start actively participating in the postoperative&#xD;
      rehabilitative process.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      The objective of the study is to evaluate the effectiveness of pecto-intercostal fascial&#xD;
      plane catheters in reducing pain on coughing 24 hours after cardiac surgery in adult&#xD;
      scheduled cardiac surgery patients undergoing complete median sternotomy.&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
      This study hypothesize that compared with placebo, bilateral pecto-intercostal fascial plane&#xD;
      catheters are effective in reducing pain on coughing in the first 24 hours after cardiac&#xD;
      surgery&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      This will be a prospective, randomized, triple-blinded, placebo-controlled trial in which&#xD;
      patients will be randomly allocated to two study groups on a 1:1 basis into:&#xD;
&#xD;
      1) Treatment Group: 20 mL of ropivacaine 0.2% will be deposited via parasternal multi-orifice&#xD;
      catheters on each side, followed by infusion of 3 mL/h for 48 hours.&#xD;
&#xD;
      2) Control Group: 20 mL of saline will be deposited via parasternal multi-orifice catheters&#xD;
      on each side, followed by infusion of 3 mL/h for 48 hours.&#xD;
&#xD;
      Statistical Analysis:&#xD;
&#xD;
      The primary outcome will be analyzed using 2 sample t-test, with both an intention-to-treat&#xD;
      and per-protocol analyses. Patients with missing outcomes (i.e. pain score at 24 hours) will&#xD;
      have their last value prior to 24 hours carried forward. Cumulative opioid consumption and&#xD;
      Quality of Recovery-15 scores will be compared using t-tests or Mann-Whitney U test, as&#xD;
      appropriate, after applying the Shapiro-Wilk test as a confirmation of normality. Frequency&#xD;
      of nausea or vomiting will be compared using Fisher's exact test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 27, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a prospective, randomized, triple-blinded, placebo-controlled trial in which patients will be randomly allocated to two study groups on a 1:1 basis into:&#xD;
1) Intervention Group: 20 mL of ropivacaine 0.2% will be bolused through PIFB catheters on each side, followed by 3 mL/hour infusion of ropivacaine 0.2% for 48 hours each side.&#xD;
2) Control Group: 20 mL of normal saline will be bolused through PIFB catheters on each side, followed by 3 mL/hour infusion of normal saline for 48 hours each side.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Patient Masking: Patients will be informed that they will receive one of two solutions (ropivacaine or saline), without disclosing which group they are allocated to.&#xD;
Anesthesiologists, cardiac surgeons, Cardiac Surgery Intensive Care Unit (CSICU) nurses, ward nurses, nurse practitioners, and acute pain service team Masking: blinded/masked to assignments.&#xD;
Assessors Masking: Assessment of patients, data collection, and follow-up will be conducted by team members (i.e. research assistant, anesthesiologist, CSICU nurses, and ward nurses, acute pain service team) will be blinded/masked to group allocation of a patient participant.&#xD;
Data Analyst Masking: The data analysts will be provided a table with two groups of the unique numbers, but which group corresponds with ropivacaine and which corresponds with normal saline will not be revealed until the data analysis has been fully completed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric rating scale (NRS) sternal pain score on coughing at 24 hours.</measure>
    <time_frame>Post-surgery, 24 hours after time zero</time_frame>
    <description>Cardiac Surgery Intensive Care Unit nurses or recovery ward nurses will assess and record Numeric Rating Scale (NRS) sternal pain scores on coughing. Coughing will be elicited with a standardized script for a sitting patient:&#xD;
&quot;Please use both hands to hold on to the pillow in front you to hold your chest in, and give me three forceful coughs in a row&quot;.&#xD;
The scale is from 0 to 10, with 0 being no pain at all and 10 being the worst pain possible.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale (NRS) sternal pain score on coughing</measure>
    <time_frame>post surgery: 8, 16, 32, 40 and 48 hours after the intervention</time_frame>
    <description>Cardiac Surgery Intensive Care Unit nurses and/or nurses in the recovery ward will assess and record Numeric Rating Scale (NRS) sternal pain scores on coughing. Coughing will be elicited with a standardized script for a sitting patient:&#xD;
&quot;Please use both hands to hold on to the pillow in front you to hold your chest in, and give me three forceful coughs in a row&quot;.&#xD;
The scale is from 0 to 10, with 0 being no pain at all and 10 being the worst pain possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative opioid consumption (in IV morphine equivalents)</measure>
    <time_frame>Post-surgery at 24 and 48 hours</time_frame>
    <description>After patient's discharge from hospital, medical record will be reviewed for opioid (in IV morphine equivalents) consumption history.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea or vomiting</measure>
    <time_frame>Post-surgery within 48 hours</time_frame>
    <description>After patient's discharge from hospital, medical record will be reviewed for nausea or vomiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Recovery-15 score (QoR-15)</measure>
    <time_frame>Post-surgery at 48 hours</time_frame>
    <description>The research assistant/research coordinator will administer Quality of Recovery-15 score (QoR-15). The QoR-15 includes Part A and Part B. Part A consists of 10 questions regarding how the patient has been feeling in the last 24 hours on a 11-point likert scale from 0 to 10, with 0 being &quot;None of the time&quot; and 10 being &quot;All of the time&quot;. Part B consists of 5 questions regarding if the patient has had any of the following in the last 24 hours on the same scale as Part A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic sternal pain</measure>
    <time_frame>Post-surgery at 3 and 6 months</time_frame>
    <description>After patient's discharge from hospital, medical record will be reviewed for complications of sternal wound infection at 3 and 6 months post-surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as measured by European Quality of Life-5 Dimension-5 Level (EQ-5D-5L)</measure>
    <time_frame>Post-surgery at 48 hours, 3 and 6 months</time_frame>
    <description>The research assistant/research coordinator will administer European Quality of Life-5 Dimension-5 Level (EQ-5D-5L).&#xD;
The EQ-5D-5L consists of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension.&#xD;
The European Quality of Life Visual Analogue Scale (VAS) records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cardiac Surgery</condition>
  <condition>Sternotomy</condition>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>Ropivacaine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants of this group will receive 20 mL of 0.2% Ropivacaine via parasternal multi-orifice catheters on each side during Sternotomy, followed by infusion of 3 mL/h for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The participants of this group will receive 20 mL of saline via parasternal multi-orifice catheters on each side during Sternotomy, followed by infusion of 3 mL/h for 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.2% Injectable Solution</intervention_name>
    <description>20 mL of ropivacaine 0.2% will be injected via parasternal multi-orifice catheters on each side, followed by infusion of 3 mL/h for 48 hours after Sternotomy.</description>
    <arm_group_label>Ropivacaine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>20 mL of saline will be injected via parasternal multi-orifice catheters on each side, followed by infusion of 3 mL/h for 48 hours after Sternotomy.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled cardiac surgery patients&#xD;
&#xD;
          -  Complete median sternotomy&#xD;
&#xD;
          -  Adult (19 years old or older)&#xD;
&#xD;
          -  English-speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Preoperative Exclusion Criteria:&#xD;
&#xD;
               -  Patient refusal&#xD;
&#xD;
               -  Emergent surgery&#xD;
&#xD;
               -  Inability to provide consent&#xD;
&#xD;
               -  Inability to follow up via telephone&#xD;
&#xD;
               -  Known preoperative coagulopathy i) Congenital coagulopathy ii) Congenital&#xD;
                  platelet disorders iii) Platelet count &lt; 50 x 109 iv) International normalized&#xD;
                  ratio (INR) or activated partial thromboplastin time (aPTT) exceeding the upper&#xD;
                  range of normal in the absence of anticoagulant use v) Does not include active&#xD;
                  anticoagulant or antiplatelet use&#xD;
&#xD;
               -  Predicted post-operative therapeutic anticoagulation within 48 hours.&#xD;
&#xD;
               -  Skin disease over block insertion site that would prevent catheter securement&#xD;
&#xD;
               -  Immunodeficiency including uncontrolled diabetes, as defined by HbA1C more than&#xD;
                  8.5% (20)&#xD;
&#xD;
               -  Preoperative advanced liver failure (as defined by Child-Pugh B or C) (21)&#xD;
&#xD;
               -  Preoperative advanced renal failure (as defined by Estimated Glomerular&#xD;
                  Filtration Rate (eGFR) &lt; 30 mL/min/1.73 m2)&#xD;
&#xD;
               -  Opioid tolerance (as defined by morphine oral equivalent &gt;60mg for a period of 7&#xD;
                  days or longer pre-operatively) (22)&#xD;
&#xD;
               -  Allergy to local anesthetic, acetaminophen, or hydromorphone&#xD;
&#xD;
               -  Weight less than 60 kg&#xD;
&#xD;
          2. Postoperative Exclusion Criteria:&#xD;
&#xD;
               -  Postoperative bleeding at time of randomization as defined by initial chest tube&#xD;
                  loss of &gt;350 mL, &gt;200 mL per hour loss, &gt; 2 mL/kg/hour loss for 2 consecutive&#xD;
                  hours, or requiring return to the operating room for surgical management (23)&#xD;
&#xD;
               -  Hemodynamic instability, as determined by CSICU attending anesthesiologist&#xD;
&#xD;
               -  Anticipated mechanical ventilation of more than 24 hours&#xD;
&#xD;
               -  Anesthesiologist unavailable to insert PIFB catheter within 4 hours of CSICU&#xD;
                  arrival&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Ree, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicola Edwards, MHA</last_name>
    <phone>778-870-5520</phone>
    <email>nedwards@providencehealth.bc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicola Edwards, MHA</last_name>
      <phone>778-870-5520</phone>
      <email>nedwards@providencehealth.bc.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/drugs/information-drug-class/opioid-analgesic-risk-evaluation-and-mitigation-strategy-rems</url>
    <description>Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) by U.S. Food and Drug Administration</description>
  </link>
  <reference>
    <citation>Liu V, Mariano ER, Prabhakar C. Pecto-intercostal Fascial Block for Acute Poststernotomy Pain: A Case Report. A A Pract. 2018 Jun 15;10(12):319-322. doi: 10.1213/XAA.0000000000000697.</citation>
    <PMID>29293481</PMID>
  </reference>
  <reference>
    <citation>Lee W, Yan YY, Jensen MP, Shun SC, Lin YK, Tsai TP, Lai YH. Predictors and patterns of chronic pain three months after cardiac surgery in Taiwan. Pain Med. 2010 Dec;11(12):1849-58. doi: 10.1111/j.1526-4637.2010.00976.x. Epub 2010 Oct 28.</citation>
    <PMID>21040435</PMID>
  </reference>
  <reference>
    <citation>van Gulik L, Janssen LI, Ahlers SJ, Bruins P, Driessen AH, van Boven WJ, van Dongen EP, Knibbe CA. Risk factors for chronic thoracic pain after cardiac surgery via sternotomy. Eur J Cardiothorac Surg. 2011 Dec;40(6):1309-13. doi: 10.1016/j.ejcts.2011.03.039. Epub 2011 May 10.</citation>
    <PMID>21561786</PMID>
  </reference>
  <reference>
    <citation>Gust R, Pecher S, Gust A, Hoffmann V, Böhrer H, Martin E. Effect of patient-controlled analgesia on pulmonary complications after coronary artery bypass grafting. Crit Care Med. 1999 Oct;27(10):2218-23.</citation>
    <PMID>10548210</PMID>
  </reference>
  <reference>
    <citation>Sasseron AB, Figueiredo LC, Trova K, Cardoso AL, Lima NM, Olmos SC, Petrucci O. Does the pain disturb the respiratory function after open heart surgery? Rev Bras Cir Cardiovasc. 2009 Oct-Dec;24(4):490-6. English, Portuguese.</citation>
    <PMID>20305922</PMID>
  </reference>
  <reference>
    <citation>Mueller XM, Tinguely F, Tevaearai HT, Revelly JP, Chioléro R, von Segesser LK. Pain location, distribution, and intensity after cardiac surgery. Chest. 2000 Aug;118(2):391-6.</citation>
    <PMID>10936130</PMID>
  </reference>
  <reference>
    <citation>Lahtinen P, Kokki H, Hynynen M. Pain after cardiac surgery: a prospective cohort study of 1-year incidence and intensity. Anesthesiology. 2006 Oct;105(4):794-800.</citation>
    <PMID>17006079</PMID>
  </reference>
  <reference>
    <citation>Milgrom LB, Brooks JA, Qi R, Bunnell K, Wuestfeld S, Beckman D. Pain levels experienced with activities after cardiac surgery. Am J Crit Care. 2004 Mar;13(2):116-25.</citation>
    <PMID>15043239</PMID>
  </reference>
  <reference>
    <citation>Mittnacht AJC, Shariat A, Weiner MM, Malhotra A, Miller MA, Mahajan A, Bhatt HV. Regional Techniques for Cardiac and Cardiac-Related Procedures. J Cardiothorac Vasc Anesth. 2019 Feb;33(2):532-546. doi: 10.1053/j.jvca.2018.09.017. Epub 2018 Sep 13. Review.</citation>
    <PMID>30529177</PMID>
  </reference>
  <reference>
    <citation>Hemmerling TM, Cyr S, Terrasini N. Epidural catheterization in cardiac surgery: the 2012 risk assessment. Ann Card Anaesth. 2013 Jul-Sep;16(3):169-77. doi: 10.4103/0971-9784.114237. Review.</citation>
    <PMID>23816670</PMID>
  </reference>
  <reference>
    <citation>Fujii S, Bairagi R, Roche M, Zhou JR. Transversus Thoracis Muscle Plane Block. Biomed Res Int. 2019 Jul 7;2019:1716365. doi: 10.1155/2019/1716365. eCollection 2019. Review.</citation>
    <PMID>31360703</PMID>
  </reference>
  <reference>
    <citation>Fujii S, Roche M, Jones PM, Vissa D, Bainbridge D, Zhou JR. Transversus thoracis muscle plane block in cardiac surgery: a pilot feasibility study. Reg Anesth Pain Med. 2019 May;44(5):556-560. doi: 10.1136/rapm-2018-100178. Epub 2019 Mar 21.</citation>
    <PMID>30902911</PMID>
  </reference>
  <reference>
    <citation>Chin KJ. An Anatomical Basis for Naming Plane Blocks of the Anteromedial Chest Wall. Reg Anesth Pain Med. 2017 May/Jun;42(3):414-415. doi: 10.1097/AAP.0000000000000575.</citation>
    <PMID>28419049</PMID>
  </reference>
  <reference>
    <citation>Murata H, Hida K, Hara T. Reply to Dr Del Buono et al. Reg Anesth Pain Med. 2016 Nov/Dec;41(6):792.</citation>
    <PMID>27776104</PMID>
  </reference>
  <reference>
    <citation>Fujii S, Vissa D, Ganapathy S, Johnson M, Zhou J. Transversus Thoracic Muscle Plane Block on a Cadaver With History of Coronary Artery Bypass Grafting. Reg Anesth Pain Med. 2017 Jul/Aug;42(4):535-537. doi: 10.1097/AAP.0000000000000607.</citation>
    <PMID>28632672</PMID>
  </reference>
  <reference>
    <citation>García Simón D, Fajardo Perez M. Safer alternatives to transversus thoracis muscle plane block. Reg Anesth Pain Med. 2019 Jul 11. pii: rapm-2019-100666. doi: 10.1136/rapm-2019-100666. [Epub ahead of print]</citation>
    <PMID>31300596</PMID>
  </reference>
  <reference>
    <citation>Fujii S. Transversus thoracis muscle plane block and alternative techniques. Reg Anesth Pain Med. 2019 Jul 11. pii: rapm-2019-100755. doi: 10.1136/rapm-2019-100755. [Epub ahead of print]</citation>
    <PMID>31300594</PMID>
  </reference>
  <reference>
    <citation>Ueshima H, Otake H. Optimal site for the subpectoral interfascial plane block. J Clin Anesth. 2017 Feb;37:115. doi: 10.1016/j.jclinane.2016.12.022. Epub 2017 Jan 9.</citation>
    <PMID>28235498</PMID>
  </reference>
  <reference>
    <citation>McDonald SB, Jacobsohn E, Kopacz DJ, Desphande S, Helman JD, Salinas F, Hall RA. Parasternal block and local anesthetic infiltration with levobupivacaine after cardiac surgery with desflurane: the effect on postoperative pain, pulmonary function, and tracheal extubation times. Anesth Analg. 2005 Jan;100(1):25-32. doi: 10.1213/01.ANE.0000139652.84897.BD.</citation>
    <PMID>15616047</PMID>
  </reference>
  <reference>
    <citation>Gianchandani RY, Saberi S, Zrull CA, Patil PV, Jha L, Kling-Colson SC, Gandia KG, DuBois EC, Plunkett CD, Bodnar TW, Pop-Busui R. Evaluation of hemoglobin A1c criteria to assess preoperative diabetes risk in cardiac surgery patients. Diabetes Technol Ther. 2011 Dec;13(12):1249-54. doi: 10.1089/dia.2011.0074. Epub 2011 Aug 21.</citation>
    <PMID>21854260</PMID>
  </reference>
  <reference>
    <citation>Jokinen MJ, Neuvonen PJ, Lindgren L, Höckerstedt K, Sjövall J, Breuer O, Askemark Y, Ahonen J, Olkkola KT. Pharmacokinetics of ropivacaine in patients with chronic end-stage liver disease. Anesthesiology. 2007 Jan;106(1):43-55.</citation>
    <PMID>17197844</PMID>
  </reference>
  <reference>
    <citation>Christensen MC, Dziewior F, Kempel A, von Heymann C. Increased chest tube drainage is independently associated with adverse outcome after cardiac surgery. J Cardiothorac Vasc Anesth. 2012 Feb;26(1):46-51. doi: 10.1053/j.jvca.2011.09.021. Epub 2011 Nov 18.</citation>
    <PMID>22100857</PMID>
  </reference>
  <reference>
    <citation>Bernstein SL, Bijur PE, Gallagher EJ. Relationship between intensity and relief in patients with acute severe pain. Am J Emerg Med. 2006 Mar;24(2):162-6.</citation>
    <PMID>16490644</PMID>
  </reference>
  <reference>
    <citation>Zubrzycki M, Liebold A, Skrabal C, Reinelt H, Ziegler M, Perdas E, Zubrzycka M. Assessment and pathophysiology of pain in cardiac surgery. J Pain Res. 2018 Aug 24;11:1599-1611. doi: 10.2147/JPR.S162067. eCollection 2018. Review.</citation>
    <PMID>30197534</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Ron Ree</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pecto-intercostal fascial plane catheters</keyword>
  <keyword>Cardiac surgery</keyword>
  <keyword>Heart surgery</keyword>
  <keyword>Sternotomy</keyword>
  <keyword>Acute pain</keyword>
  <keyword>Post-sternotomy pain</keyword>
  <keyword>Chronic Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data (IPD) will not be shared with other researchers.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 17, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT05054179/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

